OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy

Phase 3OCU410Positive

AI Analysis

Summary

Ocular Therapeutix is advancing its gene therapy OCU410 into Phase III trials for the treatment of geographic atrophy. This represents progression of the company's gene therapy program in ophthalmology.

Clinical Trial Data

Phase

III

Importance:6/10

Sentiment:

0.30

gene therapyphase 3geographic atrophyclinical development

Related Companies

$OCGN

Read the original article

Published by yahoo_finance on September 2, 2026 2:52 PM

Read Original